Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy

Shima,Hiroaki; Kutomi,Goro; Kuga,Yoko; Wada,Asaka; Satomi,Fukino; Sato,Kiminori; Kyuno,Daisuke; Nishikawa,Noriko; Uno,Satoko; Kameshima,Hidekazu; Ohmura,Tosei; Hasegawa,Tadashi; Takemasa,Ichiro

doi:10.3892/etm.2022.11767

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy

Authors:
- Hiroaki Shima
- Goro Kutomi
- Yoko Kuga
- Asaka Wada
- Fukino Satomi
- Kiminori Sato
- Daisuke Kyuno
- Noriko Nishikawa
- Satoko Uno
- Hidekazu Kameshima
- Tosei Ohmura
- Tadashi Hasegawa
- Ichiro Takemasa
View Affiliations

Affiliations: Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Hokkaido 060‑8543, Japan, Sapporo Kitaguchi Clinic, Sapporo, Hokkaido 060‑0807, Japan, Department of Surgery, Muroran City General Hospital, Muroran, Hokkaido 051‑8512, Japan, Odori Breast Thyroid Gland Clinic, Sapporo, Hokkaido 060‑0061, Japan, Department of Surgery, Higashi Sapporo Hospital, Sapporo, Hokkaido 003‑8585, Japan, Department of Surgical Pathology, Sapporo Medical University Sapporo, Hokkaido 060‑8543, Japan
Published online on: December 13, 2022 https://doi.org/10.3892/etm.2022.11767
Article Number: 68
Copyright: © Shima et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proper use of anthracycline‑containing regimens in combination with anti‑HER2‑targeted therapy in a neoadjuvant setting for patients with HER2‑positive breast cancer has not been resolved. Regimens preceded by anthracyclines have become the standard of care, and although the order has no significant impact on HER2‑negative breast cancer, it is inconclusive as to whether a taxane‑first sequence would have a similar effect on HER2‑positive breast cancer. The present study aimed to investigate the benefit of a taxane‑first sequence and of adriamycin and cyclophosphamide (AC) in patients with non‑clinical complete response (non‑cCR) to pertuzumab, trastuzumab and docetaxel (PTD). The present single‑center prospective observational study was performed to investigate PTD followed by AC, and aimed to clarify the cCR rate after PTD alone and the pathological clinical response (pCR) rate after subsequent AC in patients without cCR after PTD alone. A total 24 patients were analyzed; of these, 14 achieved pCR (pCR rate, 58.3%). While four of 14 patients (28.6%) in the intention‑to‑treat population achieved pCR, nine of 14 patients (64.3%) achieved pCR with AC but not cCR after PTD. The median tumor reduction rate after four cycles of PTD was 58.9% (range, 20.8‑100%) in all 24 patients, whereas the reduction rate after PTD‑AC was 76.9% (range, 31.1‑100%). Cardiac serious adverse events occurred in three patients (12.5%). In conclusion, a high pCR rate was observed for the taxane‑first sequence. Patients were highly responsive to PTD, but some cases achieved additional antitumor effects after AC, which resulted in pCR without cCR after PTD alone. Since cardiotoxicity remains a significant problem, a higher risk‑benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN‑CTR, date of registration: December 10, 2021.

View Figures

View References

1	Howlader N, Cronin KA, Kurian AW and Andridge R: Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 27:619–626. 2018.PubMed/NCBI View Article : Google Scholar
2	Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomized multicentre, open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012.PubMed/NCBI View Article : Google Scholar
3	Wildiers H, Forceville K, Paridaens R and Joensuu H: Taxanes and anthracyclines in early breast cancer: Which first? Lancet Oncol. 11:219–220. 2010.PubMed/NCBI View Article : Google Scholar
4	Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, et al: Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): An open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol. 15:201–212. 2014.PubMed/NCBI View Article : Google Scholar
5	Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y and Toi M: Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol. 41:867–875. 2011.PubMed/NCBI View Article : Google Scholar
6	Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, et al: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer trial. J Clin Oncol. 27:5685–5692. 2009.PubMed/NCBI View Article : Google Scholar
7	Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, et al: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 24:2278–2284. 2013.PubMed/NCBI View Article : Google Scholar
8	Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.PubMed/NCBI View Article : Google Scholar
9	van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomized, phase 3 trial. Lancet Oncol. 19:1630–1640. 2018.PubMed/NCBI View Article : Google Scholar
10	van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, et al: Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: A secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 7:978–984. 2021.PubMed/NCBI View Article : Google Scholar
11	Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, et al: 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17:791–800. 2016.PubMed/NCBI View Article : Google Scholar
12	Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011.PubMed/NCBI View Article : Google Scholar
13	Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE Jr, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, et al: Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: Subgroup analyses from KATHERINE. Ann Oncol. 32:1005–1014. 2021.PubMed/NCBI View Article : Google Scholar
14	Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, et al: Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: A meta-analysis. JAMA Oncol. 2:751–760. 2016.PubMed/NCBI View Article : Google Scholar
15	Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, et al: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol. 28:2024–2031. 2010.PubMed/NCBI View Article : Google Scholar
16	Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al: Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 382:610–621. 2020.PubMed/NCBI View Article : Google Scholar
17	File D, Curigliano G and Carey LA: Escalating and de-escalating therapy for early-stage HER2-positive breast cancer. Am Soc Clin Oncol Educ Book. 40:1–11. 2020.PubMed/NCBI View Article : Google Scholar
18	Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, et al: Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 37:1868–1875. 2019.PubMed/NCBI View Article : Google Scholar
19	Pernas S and Tolaney SM: Management of early-stage human epidermal growth factor receptor 2-positive breast cancer. JCO Oncol Pract. 17:320–330. 2021.PubMed/NCBI View Article : Google Scholar
20	Fujita N, Fujita K, Kim SJ, Iguchi C, Nomura T, Aono T, Yanagisawa T, Enomoto Y, Inakami K, Miyagawa Y, et al: Response-guided omission of anthracycline in patients with HER2-positive early breast cancer treated with neoadjuvant taxane and trastuzumab: 5-Year follow-up of prognostic study using propensity score matching. Oncology. 100:257–266. 2022.PubMed/NCBI View Article : Google Scholar
21	von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 377:122–131. 2017.PubMed/NCBI View Article : Google Scholar
22	von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.PubMed/NCBI View Article : Google Scholar
23	Yu N, Leung VWY and Meterissian S: MRI performance in detecting pCR after neoadjuvant chemotherapy by molecular subtype of breast cancer. World J Surg. 43:2254–2261. 2019.PubMed/NCBI View Article : Google Scholar
24	Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, von Minckwitz G, Brennan ME and Ciatto S: Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 105:321–333. 2013.PubMed/NCBI View Article : Google Scholar
25	Iwase M, Sawaki M, Hattori M, Yoshimura A, Ishiguro J, Kotani H, Gondo N, Adachi Y, Kataoka A, Onishi S, et al: Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery. Breast Cancer. 25:583–589. 2018.PubMed/NCBI View Article : Google Scholar
26	Yuan Y, Chen XS, Liu SY and Shen KW: Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: A meta-analysis. AJR Am J Roentgenol. 195:260–268. 2010.PubMed/NCBI View Article : Google Scholar
27	Heil J, Schaefgen B, Sinn P, Richter H, Harcos A, Gomez C, Stieber A, Hennigs A, Rauch G, Schuetz F, et al: Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. 69:142–150. 2016.PubMed/NCBI View Article : Google Scholar
28	Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, et al: Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 113:1565–1570. 2015.PubMed/NCBI View Article : Google Scholar
29	Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, et al: Annual report of the Japanese breast cancer registry for 2017. Breast Cancer. 27:803–809. 2020.PubMed/NCBI View Article : Google Scholar